Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)

NCT05658237 is registered in ClinicalTrials.gov with PharmaBio Corporation as lead sponsor.

NCT NCT05658237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05658237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)
Lead sponsor
PharmaBio Corporation
Phase
Not applicable
Overall status
Active, not recruiting
Start date
February 17, 2023
Completion date
September 30, 2027
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myopic chorioretinal atrophy